EGFR and non-small cell lung carcinoma: Therefore, in non-small cell lung cancer and colorectal cancer it is important also as a therapeutic target, where in case of mutation either tyrosine kinase inhibitors or monoclonal antibodies against EGFR are used in routine practice [2].